HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farese, A. M. Articles by MacVittie, T. J. Search for Related Content PubMed PubMed Citation Articles by Farese, A. M. Articles by MacVittie, T. J.

Promegapoietin-1a, an Engineered Chimeric IL-3 and Mpl-L Receptor Agonist, Stimulates Hematopoietic Recovery in Conventional and Abbreviated Schedules Following Radiation-Induced Myelosuppression in Nonhuman Primates

^a Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, USA;
^b Pharmacia Corporation, St. Louis, Missouri, USA

Key Words. Promegapoietin-1a • Myelosuppression • Nonhuman primate • Platelet • Hematopoiesis

Ann M. Farese, M.S., Greenebaum Cancer Center, University of Maryland, 655 West Baltimore St., BRB 7-047, Baltimore, Maryland 21201, USA. Telephone: 410-328-5347; Fax: 410-328-5488; e-mail: afarese{at}umaryland.edu

Promegapoietin-1a (PMP-1a), a multifunctional agonist for the human interleukin 3 and Mpl receptors, was evaluated for its ability to stimulate hematopoietic reconstitution in nonhuman primates following severe radiation-induced myelosuppression. Animals were total body x-irradiated (250 kVp) to 600 cGy total midline tissue dose. PMP-1a was administered s.c. in several protocols: A) daily (50 µg/kg) for 18 days; B) nine doses (5 µg/kg) every other day for 3 weeks; C) a single high dose (100 µg/kg) at 20 hours, or D) a single high dose (100 µg/kg) at 1 hour following TBI. The irradiation controls received 0.1% autologous serum for 18 consecutive days. Hematopoietic recovery was assessed by bone marrow clonogenic activity, peripheral blood cell nadirs, duration of cytopenias, time to recovery to cellular thresholds, and requirements for clinical support. PMP-1a, irrespective of administration schedule, significantly improved all platelet-related parameters: thrombocytopenia was eliminated, the severity of platelet nadirs was significantly improved, and recovery of platelet counts to 20,000/µl was significantly reduced in all PMP-1a-treated cohorts. As a consequence, all PMP-1a-treated cohorts were transfusion-independent. Neutrophil regeneration was augmented in all treatment schedules. Additionally, all PMP-1a-treated cohorts showed an improvement in red blood cell nadir and recovery. PMP-1a in conventional or abbreviated schedules induced significant thrombopoietic regeneration relative to the control cohort, whereas significant improvement in neutrophil recovery was schedule-dependent in radiation-myelosuppressed nonhuman primates.

This article has been cited by other articles:

				R. Kurzrock Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited Clin. Cancer Res., February 15, 2005; 11(4): 1361 - 1367. [Abstract] [Full Text] [PDF]

				M. Drouet, F. Mourcin, N. Grenier, V. Leroux, J. Denis, J.-F. Mayol, P. Thullier, J.-J. Lataillade, and F. Herodin Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: long-term follow-up of hematopoiesis Blood, February 1, 2004; 103(3): 878 - 885. [Abstract] [Full Text] [PDF]

				F. Herodin, P. Bourin, J.-F. Mayol, J.-J. Lataillade, and M. Drouet Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma -irradiation promotes survival Blood, April 1, 2003; 101(7): 2609 - 2616. [Abstract] [Full Text] [PDF]

				A. M. Farese, T. J. MacVittie, L. Roskos, and R. B. Stead Hematopoietic Recovery Following Autologous Bone Marrow Transplantation in a Nonhuman Primate: Effect of Variation in Treatment Schedule with PEG-rHuMGDF Stem Cells, January 1, 2003; 21(1): 79 - 89. [Abstract] [Full Text] [PDF]

				I. C. Haznedaroglu, H. Goker, M. Turgut, Y. Buyukasik, and M. Benekli Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 193 - 212. [Abstract] [PDF]